Expanded Multifunctional Angioplasty Catheter Product Line for BTK Procedures CAMBRIDGE, Massachusetts, July 17, 2024— Summa Therapeutics, a specialty angioplasty balloon medical device company, announced today that “Gen 2” of Summa’s revolutionary Finesse InjectableTM angioplasty balloon catheters has been cleared by the FDA for PTA treatment of peripheral artery disease including, among others, infra-popliteal (“below-the-knee”) arteries.…
Read more
CAMBRIDGE, Massachusetts, January 17, 2024— Summa Therapeutics, LLC announced today that the first-in-man injectable angioplasty procedures for patients with below-knee peripheral arterial disease (PAD) were performed successfully using its Finesse InjectableTM angioplasty balloon catheter platform. The Summa Finesse Injectable catheter is the industry’s first hybrid diagnostic and therapeutic angioplasty balloon catheter developed to facilitate treatment…
Read more
FDA Clears Revolutionary Injectable Angioplasty Balloon Product Line For Market Release. PROVIDENCE, Rhode Island, November 29, 2023— Summa Therapeutics, a specialty angioplasty balloon medical device company, announced today that its innovative line of injectable angioplasty balloon catheters has been cleared for marketing by the U.S. Food and Drug Administration for the treatment of peripheral artery…
Read more
